Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  zoledronic acid
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 111 for your search:
Start Over
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446GUS45, ZENITH, NCT00063609
A Multiple Myeloma Trial in Patients With Bone Metastases
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EUS97, US97, NCT00104104
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EIT04, NCT00219219
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446GGR01, NCT00219271
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EDE06, NCT00171964
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EDE15, NCT00172003
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EDE28, NCT00334139
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446GDE22, NCT00391690
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EAU22, NCT00434447
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EUS129, NCT00622505
Stage I Multiple Myeloma Treatment
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: IFM-04-01, NCT00733538
Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: CZOL446ECN06T, NCT00762346
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: CZOL446ECN07, NCT00765687
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Phase: Phase IV
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: AZABACHE: 2009-017440-13, NCT01087008
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EUS147, NCT01129336
The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011349-01H, NCT01907880
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446GDE19, NCT00375752
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CZOL446ECN05, NCT00524849
Phase III Randomized Study of Zoledronate Versus Pamidronate in Patients With Cancer-Related Bone Lesions Due to Multiple Myeloma or Breast Cancer
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NOVARTIS-4244603010, UCLA-9911015
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067052, NOVARTIS-4244603011, NCT00003884
Phase III Randomized Study of Zoledronate in Patients With Bone Metastases Secondary to Prostate Cancer (Summary Last Modified 12/1999)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NOVARTIS-4244603039
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 40 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068781, U10CA031946, CALGB-79809, NCI-P01-0184, NCT00022087
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000069274, U10CA021115, E-E1A00, E1A00, NCT00033332
Start Over